{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:04:58Z","timestamp":1791612298242,"version":"4.3.4"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2019\/33\/B\/NZ7\/02699"],"award-info":[{"award-number":["2019\/33\/B\/NZ7\/02699"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Ministerstwo Edukacji i Nauki","doi-asserted-by":"publisher","award":["2\/566516\/SPUB\/SP\/2023"],"award-info":[{"award-number":["2\/566516\/SPUB\/SP\/2023"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Schizophrenia is a mental disorder with multifactorial etiology including positive, negative and cognitive symptoms. Nitric oxide (NO\u0597)-related biochemical pathways significantly contribute to the disease\u2019s pathophysiology and subsequent antipsychotic treatment. Recently, metabotropic glutamatergic (mGlu) or muscarinic (M) receptors have been considered as potent antipsychotics with the potential to reverse cognitive symptoms. The aim of this study was to investigate how selected mGlu or muscarinic receptor ligands regulate the most important aspects of NO\u0597-related neurotransmission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, MK-801\u2014the tool compound that induces schizophrenia-related changes\u2014was used alone or with mGlu or muscarinic receptor ligands. Positive allosteric modulators (PAM) of mGlu\n                      <jats:sub>2<\/jats:sub>\n                      (LY487379), mGlu\n                      <jats:sub>5<\/jats:sub>\n                      (CDPPB), M\n                      <jats:sub>1<\/jats:sub>\n                      (VU0357017) and M\n                      <jats:sub>4<\/jats:sub>\n                      (VU0152100) receptors were administered. cGMP levels, superoxide dismutase (SOD) activity, nitrite and GLT-1\u00a0s-nitrosilation processes were investigated in mouse brain and plasma samples, while oxidative stress was measured in vitro with the use of mouse or human astrocytic cell lines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MK-801 did not change cGMP levels, while a decrease was observed in mice treated with VU0357017 or LY487379 in parallel. Increased SOD activity was observed in the cortex of MK-801-treated mice, and the compounds, with the exception of CDPPB, prevented this effect. The investigated compounds also prevented an MK-801-induced increase in plasma nitrite levels. GLT-1 protein was decreased after MK-801 treatment which was not evident in mice administered with muscarinic or mGlu ligands. GLT-1\u00a0S-nitrosilation was increased in all groups. In vitro studies revealed the potency of these compounds in counteracting MK-801-induced oxidative stress.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present data confirm that both mGlu and muscarinic receptor ligands may exert antipsychotic effects through biochemical pathways regulated by NO\u0597, in particular by decreasing oxidative stress indicators.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43440-025-00752-3","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T03:52:59Z","timestamp":1750737179000},"page":"1309-1322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of muscarinic and mGlu receptors modulators on MK-801-induced impairments in NO-dependent processes both in vitro and in vivo"],"prefix":"10.1007","volume":"77","author":[{"given":"Grzegorz","family":"Burnat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Santocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Kalinowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Wiero\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"752_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00415-024-12734-1","volume":"272","author":"B Palushaj","year":"2025","unstructured":"Palushaj B, Lewis SJG, Abdelnour C. What is the future for dementia with lewy bodies? J Neurol. 2025;272:43. https:\/\/doi.org\/10.1007\/s00415-024-12734-1.","journal-title":"J Neurol"},{"key":"752_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1176\/appi.ajp.2020.20040405","volume":"177","author":"NH Kalin","year":"2020","unstructured":"Kalin NH. New findings related to cognition, intellectual disability, dementia, and autism. Am J Psychiatry. 2020;177:473\u20135. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20040405.","journal-title":"Am J Psychiatry"},{"key":"752_CR3","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1212\/01.wnl.0000242630.52203.8f","volume":"67","author":"JE Galvin","year":"2006","unstructured":"Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology. 2006;67:1605\u201311. https:\/\/doi.org\/10.1212\/01.wnl.0000242630.52203.8f.","journal-title":"Neurology"},{"key":"752_CR4","doi-asserted-by":"publisher","first-page":"S760","DOI":"10.1192\/j.eurpsy.2024.1583","volume":"67","author":"V Moraiti","year":"2024","unstructured":"Moraiti V, Porfyri GN. Schizophrenia and risk of dementia: A literature review. Eur Psychiatry. 2024;67:S760\u20131. https:\/\/doi.org\/10.1192\/j.eurpsy.2024.1583.","journal-title":"Eur Psychiatry"},{"key":"752_CR5","doi-asserted-by":"publisher","first-page":"115325","DOI":"10.1016\/j.bcp.2022.115325","volume":"206","author":"NS Bryan","year":"2022","unstructured":"Bryan NS. Nitric oxide deficiency is a primary driver of hypertension. Biochem Pharmacol. 2022;206:115325. https:\/\/doi.org\/10.1016\/j.bcp.2022.115325.","journal-title":"Biochem Pharmacol"},{"key":"752_CR6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.biopha.2017.10.122","volume":"97","author":"J Chen","year":"2018","unstructured":"Chen J, Ye Z, Wang X, Chang J, Yang M, Zhong H, et al. Nitric oxide bioavailability dysfunction involves in atherosclerosis. Biomed Pharmacother. 2018;97:423\u20138. https:\/\/doi.org\/10.1016\/j.biopha.2017.10.122.","journal-title":"Biomed Pharmacother"},{"key":"752_CR7","doi-asserted-by":"publisher","unstructured":"Heuberger DM, Schuepbach RA. Correction to: Protease-activated receptors (PARs): Mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases (Thrombosis Journal (2019) 17: 4 DOI: 10.1186\/s12959-019-0194-8). Thromb J 2019;17:1\u201324. https:\/\/doi.org\/10.1186\/s12959-019-0212-x","DOI":"10.1186\/s12959-019-0212-x"},{"key":"752_CR8","doi-asserted-by":"publisher","unstructured":"Lee H-M, Choi JW, Choi MS. Role of nitric oxide and protein S-Nitrosylation in Ischemia-Reperfusion injury. Antioxid (Basel). 2021;11. https:\/\/doi.org\/10.3390\/antiox11010057.","DOI":"10.3390\/antiox11010057"},{"key":"752_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s10048-025-00803-0","volume":"26","author":"ZI Bahdar","year":"2025","unstructured":"Bahdar ZI, Abu-El-Rub E, Almazari R, Alzu\u2019bi A, Al-Zoubi RM. The molecular mechanism of nitric oxide in memory consolidation and its role in the pathogenesis of memory-related disorders. Neurogenetics. 2025;26:22. https:\/\/doi.org\/10.1007\/s10048-025-00803-0.","journal-title":"Neurogenetics"},{"key":"752_CR10","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1111\/bph.14800","volume":"177","author":"K Chachlaki","year":"2020","unstructured":"Chachlaki K, Prevot V. Nitric oxide signalling in the brain and its control of bodily functions. Br J Pharmacol. 2020;177:5437\u201358. https:\/\/doi.org\/10.1111\/bph.14800.","journal-title":"Br J Pharmacol"},{"key":"752_CR11","doi-asserted-by":"publisher","first-page":"7617","DOI":"10.1016\/S0021-9258(17)41011-8","volume":"252","author":"T Deguchi","year":"1977","unstructured":"Deguchi T. Endogenous activating factor for guanylate cyclase in synaptosomal-soluble fraction of rat brain. J Biol Chem. 1977;252:7617\u20139.","journal-title":"J Biol Chem"},{"key":"752_CR12","doi-asserted-by":"publisher","unstructured":"Knowles RG, Palacios M, Palmer RM, Moncada S. Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proceedings of the National Academy of Sciences. 1989;86:5159\u201362. https:\/\/doi.org\/10.1073\/pnas.86.13.5159","DOI":"10.1073\/pnas.86.13.5159"},{"key":"752_CR13","doi-asserted-by":"publisher","unstructured":"Bredt DS, Snyder SH. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proceedings of the National Academy of Sciences. 1989;86:9030\u20133. https:\/\/doi.org\/10.1073\/pnas.86.22.9030","DOI":"10.1073\/pnas.86.22.9030"},{"key":"752_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/336385a0","volume":"336","author":"J Garthwaite","year":"1988","unstructured":"Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature. 1988;336:385\u20138. https:\/\/doi.org\/10.1038\/336385a0.","journal-title":"Nature"},{"key":"752_CR15","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1523\/JNEUROSCI.23-05-01941.2003","volume":"23","author":"CLM Bon","year":"2003","unstructured":"Bon CLM, Garthwaite J. On the role of nitric oxide in hippocampal Long-Term potentiation. J Neurosci. 2003;23:1941\u20138. https:\/\/doi.org\/10.1523\/JNEUROSCI.23-05-01941.2003.","journal-title":"J Neurosci"},{"key":"752_CR16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/antiox12030753","volume":"12","author":"O-M Iova","year":"2023","unstructured":"Iova O-M, Marin G-E, Lazar I, Stanescu I, Dogaru G, Nicula CA, et al. Nitric oxide\/nitric oxide synthase system in the pathogenesis of neurodegenerative disorders: an overview. Antioxidants. 2023;12:753. https:\/\/doi.org\/10.3390\/antiox12030753.","journal-title":"Antioxidants"},{"key":"752_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/00001756-199310000-00024","volume":"5","author":"DS Lorrain","year":"1993","unstructured":"Lorrain DS, Hull EM. Nitric oxide increases dopamine and serotonin release in the medial preoptic area. NeuroReport. 1993;5:87\u20139. https:\/\/doi.org\/10.1097\/00001756-199310000-00024.","journal-title":"NeuroReport"},{"key":"752_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/s0959-4388(97)80065-7","volume":"7","author":"JE Brenman","year":"1997","unstructured":"Brenman JE, Bredt DS. Synaptic signaling by nitric oxide. Curr Opin Neurobiol. 1997;7:374\u20138. https:\/\/doi.org\/10.1016\/s0959-4388(97)80065-7.","journal-title":"Curr Opin Neurobiol"},{"key":"752_CR19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.nuclcard.2005.09.006","volume":"12","author":"MS Lauer","year":"2005","unstructured":"Lauer MS. Can the ST segment be saved? J Nucl Cardiol. 2005;12:622\u20134. https:\/\/doi.org\/10.1016\/j.nuclcard.2005.09.006.","journal-title":"J Nucl Cardiol"},{"key":"752_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1159\/000054390","volume":"68","author":"HG Bernstein","year":"1998","unstructured":"Bernstein HG, Keilhoff G, Seidel B, Stanarius A, Huang PL, Fishman MC, et al. Expression of hypothalamic peptides in mice lacking neuronal nitric oxide synthase: reduced beta-END immunoreactivity in the arcuate nucleus. Neuroendocrinology. 1998;68:403\u201311. https:\/\/doi.org\/10.1159\/000054390.","journal-title":"Neuroendocrinology"},{"key":"752_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/s0920-9964(01)00388-7","volume":"58","author":"G Xing","year":"2002","unstructured":"Xing G, Chavko M, Zhang L-X, Yang S, Post RM. Decreased calcium-dependent constitutive nitric oxide synthase (cNOS) activity in prefrontal cortex in schizophrenia and depression. Schizophr Res. 2002;58:21\u201330. https:\/\/doi.org\/10.1016\/s0920-9964(01)00388-7.","journal-title":"Schizophr Res"},{"key":"752_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41398-024-03157-7","volume":"14","author":"A Zinellu","year":"2024","unstructured":"Zinellu A, Tommasi S, Carru C, Sotgia S, Mangoni AA. A systematic review and meta-analysis of nitric oxide-associated arginine metabolites in schizophrenia. Transl Psychiatry. 2024;14:439. https:\/\/doi.org\/10.1038\/s41398-024-03157-7.","journal-title":"Transl Psychiatry"},{"key":"752_CR23","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/mp.2015.90","volume":"21","author":"SG Fillman","year":"2016","unstructured":"Fillman SG, Weickert TW, Lenroot RK, Catts SV, Bruggemann JM, Catts VS, et al. Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced broca\u2019s area volume. Mol Psychiatry. 2016;21:1090\u20138. https:\/\/doi.org\/10.1038\/mp.2015.90.","journal-title":"Mol Psychiatry"},{"key":"752_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12974-017-0962-y","volume":"14","author":"D Boerrigter","year":"2017","unstructured":"Boerrigter D, Weickert TW, Lenroot R, O\u2019Donnell M, Galletly C, Liu D, et al. Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder. J Neuroinflammation. 2017;14:188. https:\/\/doi.org\/10.1186\/s12974-017-0962-y.","journal-title":"J Neuroinflammation"},{"key":"752_CR25","doi-asserted-by":"publisher","unstructured":"Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine alterations in schizophrenia: an updated review. Front Psychiatry. 2019;10. https:\/\/doi.org\/10.3389\/fpsyt.2019.00892.","DOI":"10.3389\/fpsyt.2019.00892"},{"key":"752_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1742-2094-10-142","volume":"10","author":"S Najjar","year":"2013","unstructured":"Najjar S, Pearlman DM, Devinsky O, Najjar A, Zagzag D. Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence. J Neuroinflammation. 2013;10:142. https:\/\/doi.org\/10.1186\/1742-2094-10-142.","journal-title":"J Neuroinflammation"},{"key":"752_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/0269881113516200","volume":"28","author":"K Burghardt","year":"2014","unstructured":"Burghardt K, Grove T, Ellingrod V. Endothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia. J Psychopharmacol. 2014;28:349\u201356. https:\/\/doi.org\/10.1177\/0269881113516200.","journal-title":"J Psychopharmacol"},{"key":"752_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.schres.2011.03.031","volume":"130","author":"VL Ellingrod","year":"2011","unstructured":"Ellingrod VL, Taylor SF, Brook RD, Evans SJ, Z\u00f6llner SK, Grove TB, et al. Dietary, lifestyle and Pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs). Schizophr Res. 2011;130:20\u20136. https:\/\/doi.org\/10.1016\/j.schres.2011.03.031.","journal-title":"Schizophr Res"},{"key":"752_CR29","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pnpbp.2013.02.015","volume":"46","author":"JQ Wu","year":"2013","unstructured":"Wu JQ, Kosten TR, Zhang XY. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;46:200\u20136. https:\/\/doi.org\/10.1016\/j.pnpbp.2013.02.015.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"752_CR30","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"Recent advances in the phencyclidine model of schizophrenia","year":"1991","unstructured":"Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301\u20138. https:\/\/doi.org\/10.1176\/ajp.148.10.1301.","journal-title":"Am J Psychiatry"},{"key":"752_CR31","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/sj.mp.4001093","volume":"7","author":"S Kapur","year":"2002","unstructured":"Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors: implications for models of schizophrenia. Mol Psychiatry. 2002;7:837\u201344. https:\/\/doi.org\/10.1038\/sj.mp.4001093.","journal-title":"Mol Psychiatry"},{"key":"752_CR32","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.bbr.2015.12.034","volume":"301","author":"G Flores","year":"2016","unstructured":"Flores G, Morales-Medina JC, Diaz A. Neuronal and brain morphological changes in animal models of schizophrenia. Behav Brain Res. 2016;301:190\u2013203. https:\/\/doi.org\/10.1016\/j.bbr.2015.12.034.","journal-title":"Behav Brain Res"},{"key":"752_CR33","doi-asserted-by":"crossref","unstructured":"Wiero\u0144ska JM, K\u0142eczek N, Wo\u017aniak M, Gruca P, \u0141aso\u0144-Tyburkiewicz M, Papp M, et al. mGlu\u2085-GABAB interplay in animal models of positive, negative and cognitive symptoms of schizophrenia. Neurochem Int. 2015;88:97\u2013109. https:\/\/doi.org\/c.","DOI":"10.1016\/j.neuint.2015.03.010"},{"key":"752_CR34","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/biom13071064","volume":"13","author":"JM Wiero\u0144ska","year":"2023","unstructured":"Wiero\u0144ska JM, Cie\u015blik P, Burnat G, Kalinowski L. Activation of metabotropic glutamate receptor (mGlu2) and muscarinic receptors (M1, M4, and M5), alone or in combination, and its impact on the acquisition and retention of learning in the Morris water maze, NMDA expression and cGMP synthesis. Biomolecules. 2023;13:1064. https:\/\/doi.org\/10.3390\/biom13071064.","journal-title":"Biomolecules"},{"key":"752_CR35","doi-asserted-by":"publisher","first-page":"173749","DOI":"10.1016\/j.pbb.2024.173749","volume":"238","author":"P Cie\u015blik","year":"2024","unstructured":"Cie\u015blik P, Rafa\u0142o-Uli\u0144ska A, Wiero\u0144ska JM. Prevention of MK-801-induced amnestic effect with combined activation of 5-HT1A and muscarinic receptors in mice. Pharmacol Biochem Behav. 2024;238:173749. https:\/\/doi.org\/10.1016\/j.pbb.2024.173749.","journal-title":"Pharmacol Biochem Behav"},{"key":"752_CR36","doi-asserted-by":"publisher","first-page":"107866","DOI":"10.1016\/j.neuropharm.2019.107866","volume":"174","author":"P Cie\u015blik","year":"2020","unstructured":"Cie\u015blik P, Domin H, Chocyk A, Gruca P, Litwa E, P\u0142oska A, et al. Simultaneous activation of mGlu2 and muscarinic receptors reverses MK-801-induced cognitive decline in rodents. Neuropharmacology. 2020;174:107866. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107866.","journal-title":"Neuropharmacology"},{"key":"752_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms222212282","volume":"22","author":"P Cie\u015blik","year":"2021","unstructured":"Cie\u015blik P, Siekierzycka A, Radulska A, P\u0142oska A, Burnat G, Bra\u0144ski P, et al. Nitric oxide-dependent mechanisms underlying mk\u2010801\u2010 or scopolamine\u2010induced memory dysfunction in animals: mechanistic studies. Int J Mol Sci. 2021;22:1\u201327. https:\/\/doi.org\/10.3390\/ijms222212282.","journal-title":"Int J Mol Sci"},{"key":"752_CR38","doi-asserted-by":"publisher","unstructured":"Cie\u015blik P, Radulska A, Burnat G, Kalinowski L, Wiero\u0144ska JM. Serotonergic\u2013muscarinic interaction within the prefrontal cortex as a novel target to reverse schizophrenia-related cognitive symptoms. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22168612.","DOI":"10.3390\/ijms22168612"},{"key":"752_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.niox.2021.12.003","volume":"119","author":"P Cie\u015blik","year":"2022","unstructured":"Cie\u015blik P, Kalinowski L, Wiero\u0144ska JM. Procognitive activity of nitric oxide inhibitors and donors in animal models. Nitric Oxide. 2022;119:29\u201340. https:\/\/doi.org\/10.1016\/j.niox.2021.12.003.","journal-title":"Nitric Oxide"},{"key":"752_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.tips.2008.10.006","volume":"30","author":"PJ Conn","year":"2009","unstructured":"Conn PJ, Lindsley CW, Jones CK. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci. 2009;30:25\u201331. https:\/\/doi.org\/10.1016\/j.tips.2008.10.006.","journal-title":"Trends Pharmacol Sci"},{"key":"752_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/npp.2011.181","volume":"37","author":"B Moghaddam","year":"2012","unstructured":"Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37:4\u201315. https:\/\/doi.org\/10.1038\/npp.2011.181.","journal-title":"Neuropsychopharmacology"},{"key":"752_CR42","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.3390\/cimb46070407","volume":"46","author":"M Monaco","year":"2024","unstructured":"Monaco M, Trebesova H, Grilli M. Muscarinic receptors and alzheimer\u2019s disease: new perspectives and mechanisms. Curr Issues Mol Biol. 2024;46:6820\u201335. https:\/\/doi.org\/10.3390\/cimb46070407.","journal-title":"Curr Issues Mol Biol"},{"key":"752_CR43","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3233\/JAD-201146","volume":"78","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Das B, Yao AY, Yan R. Metabotropic glutamate receptors in alzheimer\u2019s disease synaptic dysfunction: therapeutic opportunities and hope for the future. J Alzheimers Dis. 2020;78:1345\u201361. https:\/\/doi.org\/10.3233\/JAD-201146.","journal-title":"J Alzheimers Dis"},{"key":"752_CR44","doi-asserted-by":"publisher","unstructured":"Perez-Garcia G, Bicak M, Buros J, Haure-Mirande J-V, Perez GM, Otero-Pagan A et al. Orally active mGluR2\/3 metabotropic antagonist pro-drug mimics the beneficial effects of physical exercise on neurogenesis, behavior, and exercise-related molecular pathways in an alzheimer\u2019s disease mouse model 2022. https:\/\/doi.org\/10.1101\/2022.01.31.477906","DOI":"10.1101\/2022.01.31.477906"},{"key":"752_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2022.1070478","volume":"13","author":"H Chen","year":"2023","unstructured":"Chen H, He T, Li M, Wang C, Guo C, Wang W, et al. Cell-type-specific synaptic modulation of mAChR on SST and PV interneurons. Front Psychiatry. 2023;13:1\u201311. https:\/\/doi.org\/10.3389\/fpsyt.2022.1070478.","journal-title":"Front Psychiatry"},{"key":"752_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-024-01385-z","volume":"16","author":"J Wang","year":"2024","unstructured":"Wang J, He Y, Chen X, Huang L, Li J, You Z, et al. Metabotropic glutamate receptor 5 (mGluR5) is associated with neurodegeneration and amyloid deposition in alzheimer\u2019s disease: A [18F]PSS232 PET\/MRI study. Alzheimers Res Ther. 2024;16:1\u201313. https:\/\/doi.org\/10.1186\/s13195-024-01385-z.","journal-title":"Alzheimers Res Ther"},{"key":"752_CR47","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3390\/molecules29030627","volume":"29","author":"A P\u0142oska","year":"2024","unstructured":"P\u0142oska A, Siekierzycka A, Cie\u015blik P, Dobrucki LW, Kalinowski L, Wiero\u0144ska JM. The impact of LY487379 or CDPPB on eNOS expression in the mouse brain and the effect of joint administration of compounds with NO\u2022 releasers on MK-801- or Scopolamine-Driven cognitive dysfunction in mice. Molecules. 2024;29:627. https:\/\/doi.org\/10.3390\/molecules29030627.","journal-title":"Molecules"},{"key":"752_CR48","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.niox.2024.11.010","volume":"154","author":"A P\u0142oska","year":"2025","unstructured":"P\u0142oska A, Radulska A, Siekierzycka A, Cie\u015blik P, Santocki M, Dobrucki IT, et al. The impact of mGlu2 or mGlu5 receptor activators on the production of l-arginine derivatives and the expression of PRMT5 or DDAH1 enzymes in animal models of cognitive decline. Nitric Oxide. 2025;154:140\u201351. https:\/\/doi.org\/10.1016\/j.niox.2024.11.010.","journal-title":"Nitric Oxide"},{"key":"752_CR49","doi-asserted-by":"crossref","unstructured":"Clineschmidt BV, Martin GE, Bunting PR. Anticonvulsant activity of (+)-5-Methyl4 0, 11-dihydrodH-di benzo[a,d]cyclohepten-5, 10-imine (MK-801), A substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. 2. 1982.","DOI":"10.1002\/ddr.430020203"},{"key":"752_CR50","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1021\/jm034015u","volume":"46","author":"MP Johnson","year":"2003","unstructured":"Johnson MP, Baez M, Jagdmann GE, Britton TC, Large TH, Callagaro DO, et al. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J Med Chem. 2003;46:3189\u201392. https:\/\/doi.org\/10.1021\/jm034015u.","journal-title":"J Med Chem"},{"key":"752_CR51","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1021\/jm049400d","volume":"47","author":"CW Lindsley","year":"2004","unstructured":"Lindsley CW, Wisnoski DD, Leister WH, O\u2019Brien JA, Lemaire W, Williams DL, et al. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N -(1,3-Diphenyl-1 H - pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J Med Chem. 2004;47:5825\u20138. https:\/\/doi.org\/10.1021\/jm049400d.","journal-title":"J Med Chem"},{"key":"752_CR52","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1021\/cn300103e","volume":"3","author":"GJ Digby","year":"2012","unstructured":"Digby GJ, Utley TJ, Lamsal A, Sevel C, Sheffler DJ, Lebois EP, et al. Chemical modification of the M 1 agonist VU0364572 reveals molecular switches in Pharmacology and a bitopic binding mode. ACS Chem Neurosci. 2012;3:1025\u201336. https:\/\/doi.org\/10.1021\/cn300103e.","journal-title":"ACS Chem Neurosci"},{"key":"752_CR53","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/npp.2014.2","volume":"39","author":"NE Byun","year":"2014","unstructured":"Byun NE, Grannan M, Bubser M, Barry RL, Thompson A, Rosanelli J, et al. Antipsychotic Drug-Like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100. Neuropsychopharmacology. 2014;39:1578\u201393. https:\/\/doi.org\/10.1038\/npp.2014.2.","journal-title":"Neuropsychopharmacology"},{"key":"752_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1559-0275-10-7","volume":"10","author":"CX Chan","year":"2013","unstructured":"Chan CX, Khan AA, Choi JH, Ng CD, Cadeiras M, Deng M, et al. Technology platform development for targeted plasma metabolites in human heart failure. Clin Proteom. 2013;10:7. https:\/\/doi.org\/10.1186\/1559-0275-10-7.","journal-title":"Clin Proteom"},{"key":"752_CR55","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1006\/niox.2000.0319","volume":"5","author":"KM Miranda","year":"2001","unstructured":"Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide. 2001;5:62\u201371. https:\/\/doi.org\/10.1006\/niox.2000.0319.","journal-title":"Nitric Oxide"},{"key":"752_CR56","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1136\/jcp.25.10.912","volume":"25","author":"R Freeman","year":"1972","unstructured":"Freeman R, King B. Technique for the performance of the nitro-blue tetrazolium (NBT) test. J Clin Pathol. 1972;25:912\u20134. https:\/\/doi.org\/10.1136\/jcp.25.10.912.","journal-title":"J Clin Pathol"},{"key":"752_CR57","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.freeradbiomed.2008.09.034","volume":"46","author":"MT Forrester","year":"2009","unstructured":"Forrester MT, Foster MW, Benhar M, Stamler JS. Detection of protein S-nitrosylation with the biotin-switch technique. Free Radic Biol Med. 2009;46:119\u201326. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2008.09.034.","journal-title":"Free Radic Biol Med"},{"key":"752_CR58","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fpsyt.2017.00083","volume":"8","author":"S Najjar","year":"2017","unstructured":"Najjar S, Pahlajani S, De Sanctis V, Stern JNH, Najjar A, Chong D. Neurovascular unit dysfunction and Blood-Brain barrier hyperpermeability contribute to schizophrenia neurobiology: A theoretical integration of clinical and experimental evidence. Front Psychiatry. 2017;8:83. https:\/\/doi.org\/10.3389\/fpsyt.2017.00083.","journal-title":"Front Psychiatry"},{"key":"752_CR59","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1253\/circj.CJ-16-0423","volume":"80","author":"ZS Katusic","year":"2016","unstructured":"Katusic ZS, Austin SA. Neurovascular protective function of endothelial nitric Oxide - Recent advances. Circ J. 2016;80:1499\u2013503. https:\/\/doi.org\/10.1253\/circj.CJ-16-0423.","journal-title":"Circ J"},{"key":"752_CR60","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.neuint.2005.11.019","volume":"48","author":"EM Eyjolfsson","year":"2006","unstructured":"Eyjolfsson EM, Brenner E, Kondziella D, Sonnewald U. Repeated injection of MK801: an animal model of schizophrenia? Neurochem Int. 2006;48:541\u20136. https:\/\/doi.org\/10.1016\/j.neuint.2005.11.019.","journal-title":"Neurochem Int"},{"key":"752_CR61","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1007\/s00213-023-06454-z","volume":"240","author":"A Janus","year":"2023","unstructured":"Janus A, Lustyk K, Pytka K. MK-801 and cognitive functions: investigating the behavioral effects of a non-competitive NMDA receptor antagonist. Psychopharmacology. 2023;240:2435\u201357. https:\/\/doi.org\/10.1007\/s00213-023-06454-z.","journal-title":"Psychopharmacology"},{"key":"752_CR62","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.tips.2008.12.002","volume":"30","author":"PJ Conn","year":"2009","unstructured":"Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci. 2009;30:148\u201355. https:\/\/doi.org\/10.1016\/j.tips.2008.12.002.","journal-title":"Trends Pharmacol Sci"},{"key":"752_CR63","doi-asserted-by":"publisher","first-page":"113201","DOI":"10.1016\/j.bbr.2021.113201","volume":"405","author":"DJ Foster","year":"2021","unstructured":"Foster DJ, Bryant ZK, Conn PJ. Targeting muscarinic receptors to treat schizophrenia. Behav Brain Res. 2021;405:113201. https:\/\/doi.org\/10.1016\/j.bbr.2021.113201.","journal-title":"Behav Brain Res"},{"key":"752_CR64","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.tips.2019.10.007","volume":"40","author":"SP Moran","year":"2019","unstructured":"Moran SP, Maksymetz J, Conn PJ. Targeting muscarinic acetylcholine receptors for the treatment of psychiatric and neurological disorders. Trends Pharmacol Sci. 2019;40:1006\u201320. https:\/\/doi.org\/10.1016\/j.tips.2019.10.007.","journal-title":"Trends Pharmacol Sci"},{"key":"752_CR65","doi-asserted-by":"publisher","first-page":"109569","DOI":"10.1016\/j.neuropharm.2023.109569","volume":"235","author":"F Nicoletti","year":"2023","unstructured":"Nicoletti F, Di Menna L, Iacovelli L, Orlando R, Zuena AR, Conn PJ, et al. GPCR interactions involving metabotropic glutamate receptors and their relevance to the pathophysiology and treatment of CNS disorders. Neuropharmacology. 2023;235:109569. https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109569.","journal-title":"Neuropharmacology"},{"key":"752_CR66","doi-asserted-by":"publisher","unstructured":"Russwurm M, Russwurm C, Koesling D, Mergia E. NO\/cGMP: The Past, the Present, and the Future, 2013, pp. 1\u201316. https:\/\/doi.org\/10.1007\/978-1-62703-459-3_1","DOI":"10.1007\/978-1-62703-459-3_1"},{"key":"752_CR67","doi-asserted-by":"publisher","unstructured":"Hofmann F, Wegener JW. cGMP-Dependent Protein Kinases (cGK), 2013, pp. 17\u201350. https:\/\/doi.org\/10.1007\/978-1-62703-459-3_2","DOI":"10.1007\/978-1-62703-459-3_2"},{"key":"752_CR68","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11011-010-9184-z","volume":"25","author":"C Montoliu","year":"2010","unstructured":"Montoliu C, Rodrigo R, Monfort P, Llansola M, Cauli O, Boix J, et al. Cyclic GMP pathways in hepatic encephalopathy. Neurological and therapeutic implications. Metab Brain Dis. 2010;25:39\u201348. https:\/\/doi.org\/10.1007\/s11011-010-9184-z.","journal-title":"Metab Brain Dis"},{"key":"752_CR69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/s0162-0134(01)00316-6","volume":"87","author":"JJ Canales","year":"2001","unstructured":"Canales JJ, Corbal\u00e1n R, Montoliu C, Llansola M, Monfort P, Erceg S, et al. Aluminium impairs the glutamate-nitric oxide-cGMP pathway in cultured neurons and in rat brain in vivo: molecular mechanisms and implications for neuropathology. J Inorg Biochem. 2001;87:63\u20139. https:\/\/doi.org\/10.1016\/s0162-0134(01)00316-6.","journal-title":"J Inorg Biochem"},{"key":"752_CR70","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0006-291X(77)91460-7","volume":"75","author":"N Miki","year":"1977","unstructured":"Miki N, Kawabe Y, Kuriyama K. Activation of cerebral guanylate cyclase by nitric oxide. Biochem Biophys Res Commun. 1977;75:851\u20136. https:\/\/doi.org\/10.1016\/0006-291X(77)91460-7.","journal-title":"Biochem Biophys Res Commun"},{"key":"752_CR71","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.schres.2015.02.013","volume":"164","author":"AR Docherty","year":"2015","unstructured":"Docherty AR, Bigdeli TB, Edwards AC, Bacanu S, Lee D, Neale MC, et al. Genome-wide gene pathway analysis of psychotic illness symptom dimensions based on a new schizophrenia-specific model of the OPCRIT. Schizophr Res. 2015;164:181\u20136. https:\/\/doi.org\/10.1016\/j.schres.2015.02.013.","journal-title":"Schizophr Res"},{"key":"752_CR72","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.neuint.2011.01.025","volume":"58","author":"J Boix","year":"2011","unstructured":"Boix J, Llansola M, Cabrera-Pastor A, Felipo V. Metabotropic glutamate receptor 5 modulates the nitric oxide-cGMP pathway in cerebellum in vivo through activation of AMPA receptors. Neurochem Int. 2011;58:599\u2013604. https:\/\/doi.org\/10.1016\/j.neuint.2011.01.025.","journal-title":"Neurochem Int"},{"key":"752_CR73","doi-asserted-by":"publisher","unstructured":"Zhuo M, Hawkins RD, Long-Term Depression. A Learning-Related type of synaptic plasticity in the mammalian central nervous system. Rev Neurosci. 1995;6. https:\/\/doi.org\/10.1515\/REVNEURO.1995.6.3.259.","DOI":"10.1515\/REVNEURO.1995.6.3.259"},{"key":"752_CR74","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/npp.2014.276","volume":"40","author":"JC Bartsch","year":"2015","unstructured":"Bartsch JC, Fidzinski P, Huck JHJ, H\u00f6rtnagl H, Kov\u00e1cs R, Liotta A, et al. Enhanced dopamine-dependent hippocampal plasticity after single MK-801 application. Neuropsychopharmacology. 2015;40:987\u201395. https:\/\/doi.org\/10.1038\/npp.2014.276.","journal-title":"Neuropsychopharmacology"},{"key":"752_CR75","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/cercor\/bht329","volume":"25","author":"K Blot","year":"2015","unstructured":"Blot K, Kimura S-I, Bai J, Kemp A, Manahan-Vaughan D, Giros B, et al. Modulation of hippocampus-prefrontal cortex synaptic transmission and disruption of executive cognitive functions by MK-801. Cereb Cortex. 2015;25:1348\u201361. https:\/\/doi.org\/10.1093\/cercor\/bht329.","journal-title":"Cereb Cortex"},{"key":"752_CR76","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11596-022-2690-5","volume":"43","author":"C-P Guo","year":"2023","unstructured":"Guo C-P, Li W-S, Liu Y, Mahaman YAR, Zhang B, Wang J-Z, et al. Inactivation of ERK1\/2-CREB pathway is implicated in MK801-induced cognitive impairment. Curr Med Sci. 2023;43:13\u201321. https:\/\/doi.org\/10.1007\/s11596-022-2690-5.","journal-title":"Curr Med Sci"},{"key":"752_CR77","doi-asserted-by":"publisher","unstructured":"Malenka RC, Bear MF. LTP, LTD. Neuron. 2004;44:5\u201321. https:\/\/doi.org\/10.1016\/j.neuron.2004.09.012.","DOI":"10.1016\/j.neuron.2004.09.012"},{"key":"752_CR78","doi-asserted-by":"publisher","first-page":"101986","DOI":"10.1016\/j.pneurobio.2020.101986","volume":"200","author":"KA Alkadhi","year":"2021","unstructured":"Alkadhi KA. NMDA receptor-independent LTP in mammalian nervous system. Prog Neurobiol. 2021;200:101986. https:\/\/doi.org\/10.1016\/j.pneurobio.2020.101986.","journal-title":"Prog Neurobiol"},{"key":"752_CR79","doi-asserted-by":"publisher","first-page":"10250","DOI":"10.1523\/JNEUROSCI.19-23-10250.1999","volume":"19","author":"Y-F Lu","year":"1999","unstructured":"Lu Y-F, Kandel ER, Hawkins RD. Nitric oxide signaling contributes to Late-Phase LTP and CREB phosphorylation in the Hippocampus. J Neurosci. 1999;19:10250\u201361. https:\/\/doi.org\/10.1523\/JNEUROSCI.19-23-10250.1999.","journal-title":"J Neurosci"},{"key":"752_CR80","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2174\/1570159x13666150421003225","volume":"14","author":"RK Senter","year":"2016","unstructured":"Senter RK, Ghoshal A, Walker AG, Xiang Z, Niswender CM, Conn PJ. The role of mGlu receptors in hippocampal plasticity deficits in neurological and psychiatric disorders: implications for allosteric modulators as novel therapeutic strategies. Curr Neuropharmacol. 2016;14:455\u201373. https:\/\/doi.org\/10.2174\/1570159x13666150421003225.","journal-title":"Curr Neuropharmacol"},{"key":"752_CR81","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.neubiorev.2010.10.008","volume":"35","author":"BKY Bitanihirwe","year":"2011","unstructured":"Bitanihirwe BKY, Woo T-UW. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2011;35:878\u201393. https:\/\/doi.org\/10.1016\/j.neubiorev.2010.10.008.","journal-title":"Neurosci Biobehav Rev"},{"key":"752_CR82","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s12640-018-9874-6","volume":"33","author":"RT Ribeiro","year":"2018","unstructured":"Ribeiro RT, Zanatta \u00c2, Amaral AU, Leipnitz G, de Oliveira FH, Seminotti B, et al. Experimental evidence that in vivo intracerebral administration of L-2-Hydroxyglutaric acid to neonatal rats provokes disruption of redox status and histopathological abnormalities in the brain. Neurotox Res. 2018;33:681\u201392. https:\/\/doi.org\/10.1007\/s12640-018-9874-6.","journal-title":"Neurotox Res"},{"key":"752_CR83","doi-asserted-by":"publisher","first-page":"104503","DOI":"10.1016\/j.neuint.2019.104503","volume":"129","author":"Y Zou","year":"2019","unstructured":"Zou Y, Zhang H, Chen X, Ji W, Mao L, Lei H. Age-dependent effects of (+)-MK801 treatment on glutamate release and metabolism in the rat medial prefrontal cortex. Neurochem Int. 2019;129:104503. https:\/\/doi.org\/10.1016\/j.neuint.2019.104503.","journal-title":"Neurochem Int"},{"key":"752_CR84","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1021\/acs.chemrev.5b00407","volume":"116","author":"M Hayyan","year":"2016","unstructured":"Hayyan M, Hashim MA, AlNashef IM. Superoxide ion: generation and chemical implications. Chem Rev. 2016;116:3029\u201385. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00407.","journal-title":"Chem Rev"},{"key":"752_CR85","doi-asserted-by":"publisher","first-page":"18515","DOI":"10.1074\/jbc.272.30.18515","volume":"272","author":"I Fridovich","year":"1997","unstructured":"Fridovich I. Superoxide anion radical (O2-.), superoxide dismutases, and related matters. J Biol Chem. 1997;272:18515\u20137. https:\/\/doi.org\/10.1074\/jbc.272.30.18515.","journal-title":"J Biol Chem"},{"key":"752_CR86","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s12640-021-00428-9","volume":"39","author":"A W\u0105sik","year":"2021","unstructured":"W\u0105sik A, Bia\u0142o\u0144 M, Jantas D, \u017barnowska M. The impact of the combined administration of 1MeTIQ and MK-801 on cell viability, oxidative stress markers, and glutamate release in the rat Hippocampus. Neurotox Res. 2021;39:1747\u201361. https:\/\/doi.org\/10.1007\/s12640-021-00428-9.","journal-title":"Neurotox Res"},{"key":"752_CR87","first-page":"2137","volume":"18","author":"H Ozyurt","year":"2014","unstructured":"Ozyurt H, Ozyurt B, Sarsilmaz M, Kus I, Songur A, Akyol O. Potential role of some oxidant\/antioxidant status parameters in prefrontal cortex of rat brain in an experimental psychosis model and the protective effects of melatonin. Eur Rev Med Pharmacol Sci. 2014;18:2137\u201344.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"22","key":"752_CR88","doi-asserted-by":"publisher","first-page":"8811","DOI":"10.3390\/ijms21228811","volume":"21","author":"P Cie\u015blik","year":"2020","unstructured":"Cie\u015blik P, Wiero\u0144ska JM. Regulation of glutamatergic activity via bidirectional activation of two select receptors as a novel approach in antipsychotic drug discovery. Int J Mol Sci. 2020;21(22):8811. https:\/\/doi.org\/10.3390\/ijms21228811.","journal-title":"Int J Mol Sci"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00752-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00752-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00752-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:04:32Z","timestamp":1758078272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00752-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["752"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00752-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6287635\/v1","asserted-by":"object"}]},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with EU Directive 2010\/63\/EU and subsequent regulations of the Polish Ministry of Agriculture and Rural Development and approved by the II Local Ethical Committee in Krakow, protocol no. 65\/2020, date of issue 12.03.2020.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors reviewed the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}